{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:23:33Z","timestamp":1761823413091,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":783,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.seizure.2011.02.009","type":"journal-article","created":{"date-parts":[[2011,3,25]],"date-time":"2011-03-25T00:22:12Z","timestamp":1301012532000},"page":"509-511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Reversible dementia and gait disturbance after prolonged use of valproic acid"],"prefix":"10.1016","volume":"20","author":[{"given":"Matthew D.","family":"Evans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Shinar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Yaari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2011.02.009_bib0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1600-0404.2006.00668.x","article-title":"Role of valproate across the ages. Treatment of epilepsy in the elderly","volume":"184","author":"Perucca","year":"2006","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.seizure.2011.02.009_bib0010","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1212\/WNL.47.3.626","article-title":"Reversible parkinsonism and cognitive impairment with chronic valproate use","volume":"47","author":"Armon","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2011.02.009_bib0015","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1212\/01.wnl.0000242882.58086.9a","article-title":"Brain pseudoatrophy and mental regression on valproate and a mitochondrial DNA mutation","volume":"67","author":"Galimberti","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2011.02.009_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1528-1157.1998.tb01270.x","article-title":"Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment","volume":"39","author":"Guerrini","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2011.02.009_bib0025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/mds.20357","article-title":"Valproate-induced parkinsonism: use of a newer pharmacovigilance tool to investigate the reporting of an unanticipated adverse event with an \u201cold\u201d drug","volume":"20","author":"Hauben","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.seizure.2011.02.009_bib0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4088\/JCP.v63n0114a","article-title":"Valproate-induced parkinsonism in a demented elderly patient","volume":"63","author":"Iijima","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.seizure.2011.02.009_bib0035","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mds.21188","article-title":"Valproate-induced Parkinsonism in epilepsy patients","volume":"22","author":"Jamora","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.seizure.2011.02.009_bib0040","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.revmed.2008.01.016","article-title":"Dementia syndrome in an elderly subject related to valproic acid use: a case report","volume":"29","author":"Manckoundia","year":"2008","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.seizure.2011.02.009_bib0045","first-page":"629","article-title":"Dementia and extrapyramidal problems caused by long-term valproic acid","volume":"55","author":"Masmoudi","year":"2000","journal-title":"Therapie"},{"key":"10.1016\/j.seizure.2011.02.009_bib0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-2006-931471","article-title":"Parkinsonism and\/or cognitive impairment with valproic acid therapy: a report of ten cases","volume":"39","author":"Masmoudi","year":"2006","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.seizure.2011.02.009_bib0055","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1017\/S0317167100026640","article-title":"Pseudoatrophy of the brain with valproic acid monotherapy","volume":"14","author":"McLachlan","year":"1987","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.seizure.2011.02.009_bib0060","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s004150050288","article-title":"Reversible parkinsonism induced by prolonged treatment with valproate","volume":"245","author":"Onofrj","year":"1998","journal-title":"J Neurol"},{"key":"10.1016\/j.seizure.2011.02.009_bib0065","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ana.410380423","article-title":"Reversible dementia and apparent brain atrophy during valproate therapy","volume":"38","author":"Papazian","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2011.02.009_bib0070","first-page":"81","article-title":"Valproate induced parkinsonism","volume":"50","author":"Park-Matsumoto","year":"1998","journal-title":"No To Shinkei"},{"key":"10.1016\/j.seizure.2011.02.009_bib0075","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1111\/j.1528-1167.2006.00711.x","article-title":"The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy","volume":"47","author":"Ristic","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2011.02.009_bib0080","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1528-1157.1994.tb02449.x","article-title":"Reversible valproate-induced extrapyramidal disorders","volume":"35","author":"Sasso","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2011.02.009_bib0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03088474","article-title":"Cognitive impairment and parkinsonism due to use of sodium valproate","volume":"40","author":"Schreur","year":"2009","journal-title":"Tijdschr Gerontol Geriatr"},{"key":"10.1016\/j.seizure.2011.02.009_bib0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1090-3798(98)80022-6","article-title":"Reversible cortical atrophy and cognitive decline induced by valproic acid","volume":"2","author":"Straussberg","year":"1998","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2011.02.009_bib0095","first-page":"391","article-title":"Reversible dementia due to valproic acid therapy","volume":"141","author":"Walstra","year":"1997","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.seizure.2011.02.009_bib0100","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0887-8994(03)00005-5","article-title":"Reversible altered consciousness with brain atrophy caused by valproic acid","volume":"28","author":"Yamanouchi","year":"2003","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2011.02.009_bib0105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/jnnp.2006.100222","article-title":"Movement disorders in patients taking anticonvulsants","volume":"78","author":"Zadikoff","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.seizure.2011.02.009_bib0110","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1528-1157.1986.tb03534.x","article-title":"Reversible valproic acid-induced dementia: a case report","volume":"27","author":"Zaret","year":"1986","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2011.02.009_bib0115","first-page":"484","article-title":"Valproate-induced reversible pseudoatrophy of the brain and hyperammonemic encephalopathy in a bipolar patient","volume":"43","author":"Abreu","year":"2009","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.seizure.2011.02.009_bib0120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.brainres.2009.09.051","article-title":"Valproate reversibly reduces neurite outgrowth by human SY5Y neuroblastoma cells","volume":"1302","author":"Qian","year":"2009","journal-title":"Brain Res"},{"key":"10.1016\/j.seizure.2011.02.009_bib0125","first-page":"343","article-title":"Role of the substantia nigra in GABA-mediated anticonvulsant actions","volume":"44","author":"Gale","year":"1986","journal-title":"Adv Neurol"},{"key":"10.1016\/j.seizure.2011.02.009_bib0130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF01962705","article-title":"Pharmacological, toxicological and neurochemical effects of delta 2(E)-valproate in animals","volume":"14","author":"Loscher","year":"1992","journal-title":"Pharm Weekbl Sci"},{"key":"10.1016\/j.seizure.2011.02.009_bib0135","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s004310050663","article-title":"Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy","volume":"156","author":"Lam","year":"1997","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.seizure.2011.02.009_bib0140","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1212\/WNL.40.12.1896","article-title":"Sensorineural hearing loss: a reversible effect of valproic acid","volume":"40","author":"Armon","year":"1990","journal-title":"Neurology"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131111000653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131111000653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:39:32Z","timestamp":1761010772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131111000653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S1059131111000653"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2011.02.009","relation":{},"ISSN":["1059-1311"],"issn-type":[{"type":"print","value":"1059-1311"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversible dementia and gait disturbance after prolonged use of valproic acid","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2011.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}